Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Clermont Ferrand – page 20

651 clinical trials in Clermont Ferrand, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Clermont Ferrand at a glance
651
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

651 trials in Clermont Ferrand

Open in trial search

Atrial fibrillation+1

Recruiting

Study on the Safety and Effectiveness of Apixaban and Warfarin for Patients with End-Stage Renal Disease on Peritoneal Dialysis and Atrial Fibrillation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Bladder cancer

Recruiting

Study of Atezolizumab After Chemo-radiotherapy for Patients with Muscle-invasive Bladder Cancer Not Eligible for Radical Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Prostate cancer

Recruiting

Study on Darolutamide and Triptorelin for Patients with Localized High-Risk Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Acute respiratory distress syndrome

Recruiting

Study on Dornase Alfa and Placebo to Reduce ARDS in Ventilated Trauma Patients in ICU

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dornase Alfa
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Breast cancer+2

Recruiting

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Institut Gustave Roussy

Retinoblastoma

Recruiting

Study on Retinoblastoma Treatment: Evaluating the Effectiveness of Topotecan, Vincristine Sulfate, and Etoposide in Patients Eligible for Conservative Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Hormone-refractory prostate cancer

Recruiting

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Rheumatoid arthritis

Recruiting

Study on Reducing JAK Inhibitor Doses in Patients with Low Disease Activity in Rheumatoid Arthritis Using Tofacitinib and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mk-1084
  • Sponsor:Merck Sharp & Dohme LLC

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure

Recruiting

Study on Stopping Beta-Blockers in Heart Failure Patients with Recovered Heart Function Using Carvedilol and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hydrochlorothiazide
  • Sponsor:Assistance Publique Hopitaux De Paris

Neuroendocrine cell hyperplasia of infancy

Recruiting

Study on the Effects of Methylprednisolone in Infants with Neuroendocrine Cell Hyperplasia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Methylprednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Clermont Ferrand

What the registry says about research in the country

01 Gastrointestinal Research

Innovative studies focusing on inflammatory bowel diseases including groundbreaking trials examining fecal microbiota transplantation in both Crohn's disease and ulcerative colitis. Research aims to evaluate new therapeutic approaches for patients with moderate to severe conditions.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Microbiota-based Therapies

These trials are exploring alternative treatment pathways for patients who have not responded to conventional therapies.

02 Oncology Studies

Comprehensive research in multiple myeloma and various cancer types, including innovative treatments for esophageal squamous cell carcinoma and pleural mesothelioma. Studies evaluate new therapeutic combinations and maintenance strategies.

  • Blood Cancer Treatments
  • Prostate Cancer Therapy
  • Biliary Tract Cancer Research

Focus on improving patient outcomes through targeted therapies and immunological approaches.

03 Autoimmune Conditions

Advanced research into rheumatoid arthritis and multiple sclerosis, investigating optimized treatment protocols and maintenance therapies. Studies aim to improve long-term disease management and patient quality of life.

  • Multiple Sclerosis Treatments
  • Rituximab Optimization
  • Antibody-based Therapies

Emphasis on developing more effective and tolerable treatment regimens.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.